Oncosimis® Biotech innovative platforms, AcceTT® & BacSec® allows targeted therapies accessible & affordable for one and all.
Biologics such as monoclonal antibodies and recombinant proteins are proven to enhance the safety and efficacy of therapy in certain disease conditions, and the global demand of targeted Biologics has catapulted intensive and extensive research and development of these molecules. This paradigm shift portends an attractive opportunity for Biologics manufacturers and Oncosimis® has already joined the trailblazers in this arena. At Oncosimis®, we are constantly looking for opportunities that allow us to bring costly Biologics within the reach of poor and needy patients across the world for their unmet clinical needs in treatment of several acute and chronic medical conditions. Our R & D specifically focuses on the curated process development and methodologies that utilizes state-of-the-art biomedical techniques. Oncosoimis® is committed to making prohibitively expensive Biologics and diagnostic kits more affordable and accessible, for millions of patients across the globe without compromising on any of the international quality standards.